The NovoTTF-100L System1

Indication

  • NovoTTF-100L is intended to treat patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) in addition to pemetrexed + cisplatin/carboplatin
NovoTTF-100L is a wearable, portable, and noninvasive therapy designed for loco-regional delivery of Tumor Treating Fields (TTFields) via transducer arrays.
Device & battery carrying bag, device & battery, transducer arrays
The device & battery carrying bag
Device (electric field generator) & battery
Transducer arrays
Device carrying bag for everyday life

NovoTTF-100L delivers treatment to the region of the tumor

Loco-regional delivery of TTFields via transducer arrays

  • Complements systemic therapies
  • Provides antimitotic activity directly at the site of the malignancy
  • Customized based on gender, body type, and tumor location2,*

Examples of array layouts2

Cross-chest example of array layout

 

Front-back and side-side example of array layout
  • 4 arrays are placed on the torso
  • Array layout is customized by Novocure® and approved by the prescriber

*Novocure will provide a customized map for array placement based on patient-specific measurements and tumor location (determined via CT scans).

References: 1. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 2. Novocure Corporate presentation. https://www.novocure.com/wp-content/uploads/ 2019/01/201901_NVCR_ Corporate_Presentation_vF-1.pdf. Published January 2019. Accessed April 16, 2019.

Next: How NovoTTF-100L works
Back to top
Indications For Use
jump to isi

The NovoTTF-100L System is indicated for the treatment of adult patients with unresect…